|1.||Dalal, Anand A: 8 articles (06/2012 - 01/2010)|
|2.||Stempel, David A: 5 articles (03/2011 - 03/2008)|
|3.||Shah, Manan: 4 articles (06/2012 - 03/2011)|
|4.||D'Souza, Anna O: 4 articles (06/2012 - 03/2011)|
|5.||Stanford, Richard H: 4 articles (05/2010 - 03/2008)|
|6.||Roberts, Melissa H: 3 articles (01/2012 - 01/2010)|
|7.||Delea, Thomas E: 3 articles (05/2010 - 03/2008)|
|8.||Hagiwara, May: 3 articles (05/2010 - 03/2008)|
|9.||Crater, Glenn: 2 articles (01/2012 - 01/2012)|
|10.||Katial, Rohit K: 2 articles (03/2011 - 01/2010)|
|1.||Asthma (Bronchial Asthma)
12/01/2009 - "Dispensing of fluticasone propionate/salmeterol combination in the summer and asthma-related outcomes in the fall."
10/01/2008 - "A retrospective study of the use of fluticasone propionate/salmeterol combination as initial asthma controller therapy in a commercially insured population."
03/01/2008 - "Effects of fluticasone propionate/salmeterol combination on asthma-related health care resource utilization and costs and adherence in children and adults with asthma."
01/01/2003 - "Improved ability to perform strenuous activities after treatment with fluticasone propionate/salmeterol combination in patients with persistent asthma."
12/01/2008 - "To assess the association between adherence with fluticasone propionate/salmeterol combination (FSC) product in a single inhaler and asthma care utilization and costs in asthma patients in typical US clinical practice. "
|2.||Chronic Obstructive Pulmonary Disease (COPD)
03/01/2011 - "To quantify healthcare use and costs associated with chronic obstructive pulmonary disease (COPD) among patients discharged from a COPD-related hospitalization or emergency department (ED) visit on a regimen of fluticasone propionate-salmeterol combination versus other inhaled maintenance therapies. "
03/01/2011 - "COPD-related healthcare utilization and costs after discharge from a hospitalization or emergency department visit on a regimen of fluticasone propionate-salmeterol combination versus other maintenance therapies."
02/01/2011 - "Predictive factors for evaluation of response to fluticasone propionate/salmeterol combination in severe COPD."
01/01/2010 - "The present non-systematic review summarizes the role of fluticasone propionate/salmeterol combination therapy in the prevention of exacerbations of COPD and its related effects on lung function, survival, health status, and healthcare costs."
01/01/2010 - "The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD."
|3.||Ipratropium (Ipratropium Bromide)
|6.||4- (2- ((6- ((2- (((2,6- dichlorophenyl)methyl)oxy)ethyl)oxy)hexyl)amino)- 1- hydroxyethyl)- 2- (hydroxymethyl)phenol
|9.||Cholinergic Antagonists (Anticholinergics)
|2.||Metered Dose Inhalers (Metered Dose Inhaler)
|3.||Nebulizers and Vaporizers (Inhaler)